5t The 1 International Moxifloxacin symposium took place in Berlin Germany February 18 - 20,1999. The purpose of this meeting was to introduce the medical and scientific communities to this exciting new fluoroquinolone and to define its role in the management of respiratory tract infections. The fluoroquinolones as a class are an important part of our therapeutic armamentarium and moxi floxacin is a unique addition to this class of compounds. This symposium brought together physician/scientists from around the world to present and discuss the moxifloxacin data. The information from this important meeting are presented in these proceedings and are organized under the following headings: Part I Antimicrobial chemotherapy Part II Pre-clinical microbiology Part III Pharmacology Part IV Clinical needs in the millennium Part V Round table discussion The modifications to the basic quinolone structure resulting in moxifloxacin have produced a drug with unique in vitro, and pharmacokinetic/pharmaco dynamic properties. The drug has a very broad spectrum of antimicrobial activity, is well absorbed and can be taken only once daily. Its profile makes it an excellent therapeutic option for many types of respiratory tract infections. It is hoped that our clinical and laboratory colleagues will be as excited by this data as we are and we look forward to further work with this unique and interesting compound.
|Publisher:||Springer Berlin Heidelberg|
|Edition description:||Softcover reprint of the original 1st ed. 2000|
|Product dimensions:||6.10(w) x 9.25(h) x (d)|
Table of Contentsto the Symposium.- 1 Antimicrobial Chemotherapy.- Antimicrobial Chemotherapy Today.- Antimicrobial Chemotherapy Tomorrow.- PART2Pre-clinical.- Pre-clinical Microbiology Streptococcus Pneumoniae.- Pre-clinical Microbiology Gram-positive Cocci.- Pre-clinical Microbiology Atypical Organisms.- Pre-clinical Microbiology Summary I.- Pre-clinical Microbiology Mycobacteria.- In-vitro Activity of Moxifloxacin [Bay 12-8039], an 8-methoxy Quinolone, Compared to Other Fluoroquinolones Against Anaerobic Bacteria.- Pre-clinical Microbiology Fastidious Gram-negative Bacteria.- Pre-clinical Microbiology Respiratory Tract Infections Susceptibility Survey USA.- Pre-clinical Microbiology Respiratory Tract Infections Susceptibility Survey Europe.- Pre-clinical Microbiology Respiratory Tract Infections Susceptibility Survey Japan.- Mechanisms of Fluoroquinolone Action and Resistance.- Pre-clinical Microbiology Summary II.- 3 Pharmacology.- Pharmacokinetics and Pharmacodynamics of Antimicrobials.- Mini-Reviews Pharmacokinetics/Pharmacodynamics (PK/PD).- In vitro Models as Predictors of the Antimicrobial Effect of Moxifloxacin and Other Fluoroquinolones.- In vitro Models of Infection Pharmacokinetic/Pharmacodynamic Correlates.- Animal Model Experiences with Moxifloxacin.- Current Thinking About Pharmacokinetics and Pharmacodynamics of Antimicrobials.- Pharmacology of Moxifloxacin Absorption, Distribution, Metabolism and Excretion.- Antimicrobial Drug-Drug Interations Focus on Fluoroquinolones.- Pharmacology Tissue Distribution.- Fluoroquinolones Phototoxicity Moxifloxacin in Context.- Fluoroquinolone Safety and Tolerability.- 4 Clinical Needs in the Millenium.- Clinical Needs in the Millenium Community Acquired Pneumonia.- Clinical Needs in the Millenium Pneumonia The Role of Moxifloxacin.- Clinical Needs in the Millenium Acute Exacerbations of Chronic Bronchitis.- Clinical Needs in the Millenium Acute Exacerbations of Chronic Bronchitis The Role of Moxifloxacin.- Clinical Needs in the Millenium Rhinosinusitis.- Clinical Needs in the Millenium Rhinosinusitis The Role of Moxifloxacin.- Discussion on Clinical Needs in the Millenium.- 5 Round Table Discussion.- Round Table Discussion Introduction.- Round Table Discussion Hospital Issues.- Round Table Discussion Community Issues.